Geron Ends Phase 3 Rytelo Study in Myelofibrosis for Futility
Geron said an independent data monitoring committee advised ending the late-stage study because it was likely to fail.
By Colin KellaherGeron Corp. is scrapping a late-stage study of its anemia drug Rytelo in the bone marrow cancer myelofibrosis because the study was likely to fail.Geron on Wednesday said the Phase 3 study's independent data monitoring committee advised the Foster City, Calif., biopharmaceutical co…